294 related articles for article (PubMed ID: 24461384)
41. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
[TBL] [Abstract][Full Text] [Related]
42. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis.
Hudson M; Taillefer S; Steele R; Dunne J; Johnson SR; Jones N; Mathieu JP; Baron M
Clin Exp Rheumatol; 2007; 25(5):754-7. PubMed ID: 18078627
[TBL] [Abstract][Full Text] [Related]
43. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy.
Ingegnoli F; Boracchi P; Gualtierotti R; Biganzoli EM; Zeni S; Lubatti C; Fantini F
Rheumatology (Oxford); 2010 Apr; 49(4):797-805. PubMed ID: 20100796
[TBL] [Abstract][Full Text] [Related]
44. Very Early Diagnosis of Systemic Sclerosis in Clinical Practice - Case Report and Review of the Literature.
Marković I; Posavec AL; Morović-Vergles J; Mitrović J
Acta Dermatovenerol Croat; 2022 Dec; 30(4):251-255. PubMed ID: 36919392
[TBL] [Abstract][Full Text] [Related]
45. Assessing microvascular changes in systemic sclerosis diagnosis and management.
Cutolo M; Sulli A; Smith V
Nat Rev Rheumatol; 2010 Oct; 6(10):578-87. PubMed ID: 20703220
[TBL] [Abstract][Full Text] [Related]
46. [Systemic sclerosis].
Kleinert S; Tony HP; Kneitz C
Internist (Berl); 2006 Oct; 47(10):1051-61; quiz 1062. PubMed ID: 16972070
[TBL] [Abstract][Full Text] [Related]
47. Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?
Valentini G; Pope JE
Autoimmun Rev; 2020 Nov; 19(11):102659. PubMed ID: 32942034
[TBL] [Abstract][Full Text] [Related]
48. Clinical diagnosis compared to classification criteria in in a cohort of 54 patients with systemic sclerosis and associated disorders.
Ziswiler HR; Urech R; Balmer J; Ostensen M; Mierau R; Villiger PM
Swiss Med Wkly; 2007 Oct; 137(41-42):586-90. PubMed ID: 17990152
[TBL] [Abstract][Full Text] [Related]
49. Systemic sclerosis with normal or nonspecific nailfold capillaroscopy.
Fichel F; Baudot N; Gaitz JP; Trad S; Barbe C; Francès C; Senet P
Dermatology; 2014; 228(4):360-7. PubMed ID: 24751944
[TBL] [Abstract][Full Text] [Related]
50. Capillaroscopy.
Cutolo M; Pizzorni C; Secchi ME; Sulli A
Best Pract Res Clin Rheumatol; 2008 Dec; 22(6):1093-108. PubMed ID: 19041079
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and management of scleroderma peripheral vascular disease.
Herrick A
Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535
[TBL] [Abstract][Full Text] [Related]
52. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
Ingegnoli F; Carmona L; Castrejon I
Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
[TBL] [Abstract][Full Text] [Related]
53. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
[TBL] [Abstract][Full Text] [Related]
54. Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions.
Bellando-Randone S; Matucci-Cerinic M
Curr Rheumatol Rep; 2017 Sep; 19(10):65. PubMed ID: 28921059
[TBL] [Abstract][Full Text] [Related]
55. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
[TBL] [Abstract][Full Text] [Related]
56. Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.
Park JS; Park MC; Song JJ; Park YB; Lee SK; Lee SW
Arthritis Res Ther; 2015 Mar; 17(1):77. PubMed ID: 25889905
[TBL] [Abstract][Full Text] [Related]
57. Microvascular abnormalities in patients with early systemic sclerosis: less severe morphological changes than in patients with definite disease.
Camargo CZ; Sekiyama JY; Arismendi MI; Kayser C
Scand J Rheumatol; 2015; 44(1):48-55. PubMed ID: 25379977
[TBL] [Abstract][Full Text] [Related]
58. Anti-topoisomerase I autoantibodies in systemic sclerosis.
Czömpöly T; Simon D; Czirják L; Németh P
Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194
[TBL] [Abstract][Full Text] [Related]
59. [Clinical and capillaroscopic regression of CD30 anaplastic lymphoma associated with limited cutaneous systemic sclerosis following autologous bone marrow transplantation].
Bellis R; Francès C; Barète S; Senet P
Ann Dermatol Venereol; 2014; 141(6-7):446-51. PubMed ID: 24951144
[TBL] [Abstract][Full Text] [Related]
60. Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.
Toki S; Motegi S; Yamada K; Uchiyama A; Kanai S; Yamanaka M; Ishikawa O
J Dermatol; 2015 Mar; 42(3):283-7. PubMed ID: 25582037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
